COVID-19 resources / Clinical Research Insights and News

The Cohortias Blog

Stay informed

COVID-19 resources

Cohortias is bringing clinical research to Latin America, now proud to participate in COVID-19 clinical trials.

Our archive includes insights from our experts as they discuss lessons learned over the past three months in managing COVID-19’s impact on trials in Latin America and around the world.

Our blog posts provide insights into what companies should be doing now to prepare for the upcoming ‘new normal’.


Cohortias – Top CROs in Latin America.

Beginning 20 years ago, healthcare enterprises began using outsourcing providers to assist in areas like Regulatory Submissions, Patient Recruitment, Project Management and Clinical Monitoring.


COVID-19 Trials in Latin America – Vaccine highly effective.

The trial results put this vaccine in the same efficacy ballpark as the mRNA vaccines produced by Pfizer-BioNTech and Moderna.


Study finds Covid vaccine effective against viral variants.

Data showed antibody and cellular immune responses against SARS-CoV-2 variants of concern as well as the original strain.


US approves first new Alzheimer’s drug in almost two decades.

U.S. regulators on Monday approved Biogen Inc’s aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease despite controversy over whether the clinical evidence proves the drug works.

COVID-19 Research - Free Consultation

The clinical development journey is fraught with pitfalls and roadblocks; COVID-19 has almost overnight added to the complexity. Innovations, technologies and reinvented processes can help. Our experienced team of experts shares experiences, lessons learned and tips to help you mitigate risk in the current environment while implementing some of the industry’s latest innovations.

covid clinical trials

The presence of clinical research in Latin America has been growing steadily for the last decade, mainly because of cost effectiveness, excellent patient recruitment and the emergence of FDA approved regulatory agencies.